Patents by Inventor Chi-Chung Li

Chi-Chung Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240132613
    Abstract: The invention provides methods of dosing for the treatment of cancers, such as B cell proliferative disorders, with anti-cluster of differentiation 20 (CD20)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.
    Type: Application
    Filed: December 6, 2023
    Publication date: April 25, 2024
    Inventors: Yu-Waye CHU, Iraj HOSSEINI, Saroja RAMANUJAN, Kapil GADKAR, Chi-Chung LI
  • Publication number: 20240130086
    Abstract: A multimode immersion cooling system includes a first, single-phase immersion cooling mode and a second, two-phase immersion cooling mode. The system operates in a single phase mode and reserves a two-phase mode for peak energy consumption periods. A single thermal transfer fluid is used for both modes, remaining in a liquid phase in a first single-phase immersion cooling mode and vaporizing when the thermal transfer fluid temperature reaches its boiling point in a second two-phase immersion cooling mode. A heat exchanger extracts thermal energy from heated thermal transfer fluid in the single phase mode while a condenser cools vaporized thermal transfer fluid to condense the vapor during the second, two-phase immersion cooling mode. A controller determines whether the multimode immersion cooling system operates in the single-phase mode or the second two-phase mode, or both.
    Type: Application
    Filed: December 22, 2023
    Publication date: April 18, 2024
    Inventors: Wai Chung LI, Chi Ho KWOK
  • Publication number: 20240043553
    Abstract: The present invention relates to the treatment of subjects having previously untreated follicular lymphoma (FL). More specifically, the invention pertains to the treatment of subjects having previously untreated FL by administering a combination of mosunetuzumab and lenalidomide.
    Type: Application
    Filed: June 21, 2023
    Publication date: February 8, 2024
    Inventors: Andrea KNAPP, Chi-Chung LI, Enkhtsetseg PUREV, Michael C. WEI
  • Patent number: 11809161
    Abstract: A system for determining a light intensity field for use in manufacturing a 3D object from a volume of material. The system receives a 3D specification of a 3D geometry for the 3D object that specifies voxels within the volume that contain material that is to be part of the 3D object. The system employs a cost function for effectiveness of a light intensity field in manufacturing the 3D object. The cost function may be an adjoint of an Attenuated Radon Transform that models an energy dose that each voxel would receive during manufacture of the 3D object using the light intensity field. The system applies an optimization technique that employs the cost function to generate a measure of the effectiveness of possible light intensity fields and outputs an indication of a light intensity field that will be effective in manufacturing the 3D object.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: November 7, 2023
    Assignees: Lawrence Livermore National Security, LLC, The Regents of the University of California
    Inventors: Maxim Shusteff, Kyle Champley, Erika Jo Fong, Hayden Taylor, Chi Chung Li, Trevor Rongey, Jr., Sui Man Luk, Heting Fu, Samira Feili, Joseph Toombs, Hossein Heidari
  • Publication number: 20230242659
    Abstract: The invention provides methods of dosing for the treatment of cancers, such as B cell proliferative disorders, with anti-cluster of differentiation 20 (CD20)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.
    Type: Application
    Filed: February 23, 2023
    Publication date: August 3, 2023
    Inventors: Yu-Waye Chu, Iraj Hosseini, Saroja Ramanujan, Kapil Gadkar, Chi-Chung Li
  • Publication number: 20230190932
    Abstract: The present invention relates to the treatment of subjects having relapsed and/or refractory (R/R) follicular lymphoma (FL). More specifically, the invention pertains to the treatment of subjects having R/R FL by administering a combination of mosunetuzumab and lenalidomide.
    Type: Application
    Filed: October 28, 2022
    Publication date: June 22, 2023
    Inventors: Catherine GRANIER, Andrea Knapp, Chi-Chung Li, Carol Elaine O'Hear, Enkhtsetseg Purev, Michael C. Wei
  • Publication number: 20220380466
    Abstract: The present invention relates to the treatment of subjects having B cell proliferative disorders (e.g., high grade B-cell lymphomas, as well as non-Hodgkin's lymphomas, such as diffuse large B-cell lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by intravenous administration of an anti-CD20/anti-CD3 bispecific antibody.
    Type: Application
    Filed: June 1, 2022
    Publication date: December 1, 2022
    Inventors: Chi-Chung LI, Carol Elaine O'HEAR, Xi CHEN
  • Patent number: 11466094
    Abstract: The invention provides methods of dosing for the treatment of cancers, such as B cell proliferative disorders, with anti-cluster of differentiation 20 (CD20)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: October 11, 2022
    Assignee: Genentech, Inc.
    Inventors: Yu-Waye Chu, Iraj Hosseini, Saroja Ramanujan, Kapil Gadkar, Chi-Chung Li
  • Publication number: 20220162329
    Abstract: The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by intravenous administration of an anti-CD20/anti-CD3 bispecific antibody (e.g., mosunetuzumab).
    Type: Application
    Filed: November 2, 2021
    Publication date: May 26, 2022
    Inventors: Chi-Chung LI, Carol Elaine O'HEAR, Brendan Christian BENDER
  • Publication number: 20220153842
    Abstract: The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder (e.g., B cell proliferative disorder) by administering a combination of an anti-CD20/anti-CD3 bispecific antibody and an anti-CD79b antibody drug conjugate.
    Type: Application
    Filed: November 2, 2021
    Publication date: May 19, 2022
    Inventors: Chi-Chung LI, Carol Elaine O'HEAR, Stephen James SIMKO, III, Iris Tranthuyngan TO, Klara TOTPAL, Hong WANG, Michael C. WEI, Shen YIN, Brendan Christian BENDER, Xi CHEN, Yu-Waye CHU, Maria HRISTOPOULOS
  • Publication number: 20220153858
    Abstract: The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by subcutaneous administration of an anti-CD20/anti-CD3 bispecific antibody.
    Type: Application
    Filed: November 2, 2021
    Publication date: May 19, 2022
    Inventors: Chi-Chung LI, Carol Elaine O'HEAR, Hong WANG, Brendan Christian BENDER, Iraj HOSSEINI
  • Publication number: 20220011742
    Abstract: A system for determining a light intensity field for use in manufacturing a 3D object from a volume of material. The system receives a 3D specification of a 3D geometry for the 3D object that specifies voxels within the volume that contain material that is to be part of the 3D object. The system employs a cost function for effectiveness of a light intensity field in manufacturing the 3D object. The cost function may be an adjoint of an Attenuated Radon Transform that models an energy dose that each voxel would receive during manufacture of the 3D object using the light intensity field. The system applies an optimization technique that employs the cost function to generate a measure of the effectiveness of possible light intensity fields and outputs an indication of a light intensity field that will be effective in manufacturing the 3D object.
    Type: Application
    Filed: July 13, 2020
    Publication date: January 13, 2022
    Inventors: Maxim Shusteff, Kyle Champley, Erika Jo Fong, Hayden Taylor, Chi Chung Li, Trevor Rongey, JR., Sui Man Luk, Heting Fu, Samira Feili, Joseph Toombs, Hossein Heidari
  • Publication number: 20180346586
    Abstract: The invention provides methods of treating or delaying progression of cancer in an individual comprising administering to the individual an anti-human OX40 agonist antibody. In some embodiments, the antibody is administered in a dose selected from about 0.2 mg, about 0.8 mg, about 3.2 mg, about 12 mg, about 40 mg, about 80 mg, about 130 mg, about 160 mg, about 300 mg, about 320 mg, about 400 mg, about 600 mg, and about 1200 mg.
    Type: Application
    Filed: May 11, 2018
    Publication date: December 6, 2018
    Applicant: Genentech, Inc.
    Inventors: Ina P. RHEE, Jeong KIM, Mahrukh HUSENI, Eric STEFANICH, Sid SUKUMARAN, Chi-Chung LI
  • Publication number: 20180256711
    Abstract: The invention provides methods of treating or delaying progression of cancer in an individual comprising administering to the individual an anti-human OX40 agonist antibody and an anti-PDL1 antibody. In some embodiments, the anti-human OX40 agonist antibody is administered in a dose selected from about 0.8 mg, about 3.2 mg, about 12 mg, about 40 mg, about 80 mg, about 130 mg, about 160 mg, about 300 mg, about 320 mg, about 400 mg, about 600 mg, and about 1200 mg, and the anti-PDL1 antibody is administered at a dose of about 800 mg or about 1200 mg.
    Type: Application
    Filed: December 14, 2017
    Publication date: September 13, 2018
    Applicant: Genentech, Inc.
    Inventors: Ina P. RHEE, Jeong KIM, Mahrukh HUSENI, Eric STEFANICH, Siddharth SUKUMARAN, Chi-Chung LI
  • Publication number: 20180134798
    Abstract: The invention provides methods of dosing for the treatment of cancers, such as B cell proliferative disorders, with anti-cluster of differentiation 20 (CD20)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.
    Type: Application
    Filed: November 15, 2017
    Publication date: May 17, 2018
    Inventors: Yu-Waye CHU, Iraj HOSSEINI, Saroja RAMANUJAN, Kapil GADKAR, Chi-Chung LI
  • Publication number: 20170000885
    Abstract: The invention provides methods of treating or delaying progression of cancer in an individual comprising administering to the individual an anti-human OX40 agonist antibody and an anti-PDL1 antibody. In some embodiments, the anti-human OX40 agonist antibody is administered in a dose selected from about 0.8 mg, about 3.2 mg, about 12 mg, about 40 mg, about 80 mg, about 130 mg, about 160 mg, about 300 mg, about 320 mg, about 400 mg, about 600 mg, and about 1200 mg, and the anti-PDL1 antibody is administered at a dose of about 800 mg or about 1200 mg.
    Type: Application
    Filed: June 7, 2016
    Publication date: January 5, 2017
    Applicant: Genentech, Inc.
    Inventors: Ina P. RHEE, Jeong KIM, Mahrukh HUSENI, Eric STEFANICH, Sid SUKUMARAN, Chi-Chung LI
  • Publication number: 20160355597
    Abstract: The invention provides methods of treating or delaying progression of cancer in an individual comprising administering to the individual an anti-human OX40 agonist antibody. In some embodiments, the antibody is administered in a dose selected from about 0.2 mg, about 0.8 mg, about 3.2 mg, about 12 mg, about 40 mg, about 80 mg, about 130 mg, about 160 mg, about 300 mg, about 320 mg, about 400 mg, about 600 mg, and about 1200 mg.
    Type: Application
    Filed: June 7, 2016
    Publication date: December 8, 2016
    Applicant: Genentech, Inc.
    Inventors: Ina P. RHEE, Jeong KIM, Mahrukh HUSENI, Eric STEFANICH, Sid SUKUMARAN, Chi-Chung LI
  • Patent number: 8071121
    Abstract: An ophthalmically bioactive agent delivery system comprising a contact lens having dispersed therein as an oil-in-water microemulsion, an ophthalmically bioactive agent encapsulated in the oil phase, the oil phase comprising a material from which the agent VAN diffuse into and migrate through the contact lens into the post-lens tear film when the contact lens is placed on the eye and wherein the microemulsion is stabilized by the presence of a surfactant with sufficient packing at the oil-water interface to attenuate the rate of diffusion into and migration of agent through the contact lens.
    Type: Grant
    Filed: September 4, 2007
    Date of Patent: December 6, 2011
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Anuj Chauhan, Derya Gulsen Onbilger, Yash Kapoor, Chi-Chung Li